Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for PA GOODDOCTOR?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥601.5M in FY2016 to CN¥5.47B in FY2025 (9-year CAGR +27.8%).
- Net income was negative in FY2016, FY2017, FY2018, FY2019, FY2020, FY2021, FY2022, FY2023.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 7.33 | 6.21 | 4.67 | 4.81 | 5.47 |
| YoY | 6.8% | -15.4% | -24.7% | 2.9% | 13.7% |
| Net Income (CNY B) | -1.54 | -0.64 | -0.32 | 0.08 | 0.38 |
| YoY | — | — | — | — | 366.1% |
| Operating Cash Flow (CNY B) | -1.40 | -0.81 | -0.28 | 0.10 | 0.45 |
| ROE | -10.3% | -4.6% | -2.4% | 1.0% | 5.6% |
| Gross Margin | 23.3% | 26.9% | 32.3% | 31.7% | 32.4% |
| Net Margin | -21.0% | -10.3% | -6.9% | 1.7% | 6.9% |
| Debt-to-Assets | 21.2% | 21.3% | 19.7% | 78.7% | 25.1% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 0.60 | 1.87 | 3.34 | 5.07 | 6.87 | 7.33 | 6.21 | 4.67 | 4.81 | 5.47 |
| YoY | — | 210.6% | 78.7% | 51.8% | 35.5% | 6.8% | -15.4% | -24.7% | 2.9% | 13.7% |
| Net Income (CNY B) | -0.76 | -1.00 | -0.91 | -0.73 | -0.95 | -1.54 | -0.64 | -0.32 | 0.08 | 0.38 |
| YoY | — | — | — | — | — | — | — | — | — | 366.1% |
| Operating Cash Flow (CNY B) | -0.26 | -0.48 | -1.09 | -0.50 | -1.10 | -1.40 | -0.81 | -0.28 | 0.10 | 0.45 |
| ROE | -31.9% | -31.3% | -12.8% | -7.4% | -7.4% | -10.3% | -4.6% | -2.4% | 1.0% | 5.6% |
| Gross Margin | 42.2% | 32.8% | 27.3% | 23.1% | 27.2% | 23.3% | 26.9% | 32.3% | 31.7% | 32.4% |
| Net Margin | -126.1% | -53.6% | -27.3% | -14.5% | -13.8% | -21.0% | -10.3% | -6.9% | 1.7% | 6.9% |
| Debt-to-Assets | 43.3% | 32.5% | 17.0% | 21.9% | 14.6% | 21.2% | 21.3% | 19.7% | 78.7% | 25.1% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Watch
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
No dividends paid over the trailing 12 months.
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.